Related Experiment Videos
Life-threatening hyperkalaemia following therapeutic barbiturate coma
Christopher J S Cairns1, Benjamin Thomas, Stephen Fletcher
1Intensive Care Unit, Royal North Shore Hospital, St. Leonards, Sydney NSW, 2065, Australia.
Intensive Care Medicine
|September 5, 2002
Summary
Therapeutic thiopentone coma can cause dangerous electrolyte shifts. Patients may develop hypokalemia during treatment and severe, life-threatening hyperkalemia after stopping thiopentone, requiring careful monitoring.
Area of Science:
- Neurosurgery
- Intensive Care Medicine
- Clinical Pharmacology
Background:
- Therapeutic coma using barbiturates like thiopentone is employed for managing severe brain injuries.
- Maintaining hemodynamic stability and electrolyte balance is critical in neurocritical care.
Observation:
- Three neurocritical care patients received thiopentone coma for conditions including traumatic brain injury and subarachnoid hemorrhage.
- Two patients experienced refractory hypokalemia during thiopentone infusion, resistant to potassium supplementation.
Findings:
- All three patients developed severe, life-threatening hyperkalemia during the recovery phase after thiopentone cessation.
- One patient experienced a fatal outcome attributed to this hyperkalemic event.
Implications:
- Clinicians must be aware of the risk of severe hypokalemia during thiopentone coma and rebound hyperkalemia post-infusion.
- Protocols for barbiturate coma management should incorporate strategies to monitor and manage these critical electrolyte disturbances.